XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

26 – 30 October 2017 | Philadelphia, USA | AACR-NCI-EORTC Conference

  The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics will be held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania, from October 26-30, 2017 with exhibit dates on October 28-29. We will be part of companies with the latest in products and services in laboratory and clinical research! On this special occasion, we […]

Company

Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....

Partnerships

Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...